NEWS & MEDIA
We’re not only at the front lines of therapeutic advancement, we’re also continuously making headlines in healthcare, business, and research markets.
PRESS RELEASES
BeyondSpring Announces Fourth Quarter and Year End 2020 Financial Results and Provides a Corporate Update
- NDAs filed in the U.S. and China in Mar. 2021 based on superior data from Phase 3 PROTECTIVE-2 trial of Breakthrough Therapy Designation regimen, plinabulin plus G-CSF vs. G-CSF alone in prevention of CIN - Company subsidiary, SEED Therapeutics, signed an $800...
BeyondSpring Announces Five Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting
- Four presentations to focus on the clinically meaningful endpoint improvement, including the reduction of febrile neutropenia and hospitalization, shown by plinabulin in the prevention of chemotherapy-induced neutropenia (CIN) - An additional presentation to focus...
BeyondSpring Announces Submission of New Drug Application to U.S. FDA and China NMPA for Plinabulin and G-CSF Combination for the Prevention of Chemotherapy-Induced Neutropenia (CIN)
– Applications are supported by positive PROTECTIVE-2 Phase 3 data demonstrating that plinabulin in combination with G-CSF offers greater protection against CIN than the standard of care, G-CSF alone – Plinabulin’s MoA is distinct from, yet complementary to that of...
BeyondSpring Hosting Key Opinion Leader Webinar on Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia
Webinar on Thursday, March 18th @ 10:00 a.m. ET NEW YORK, March 11, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced...
BeyondSpring to Present at the J.P. Morgan Healthcare Conference on January 14, 2021
NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that CEO Dr. Lan Huang is scheduled to present...
MEDIA
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.